Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | BAD | Q92934 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPN | P05981 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7517744 | 0.88 | BCL2L1 (0.48) | PARP1BCL2L1BADDRD2MEN1 | |
| SCHEMBL28507933 | 0.86 | BCL2L1 (0.52) | PARP1BCL2L1BADDRD2MEN1 | |
| SCHEMBL6577620 | 0.79 | PARP1 (0.41) | PARP1BCL2L1BADDRD2MEN1 | |
| SCHEMBL6700650 | 0.77 | BCL2L1 (0.45) | PARP1BCL2L1BADDRD2MEN1 | |
| SCHEMBL6465805 | 0.77 | — | — | |
| SCHEMBL2994306 | 0.75 | SSTR4 (0.44) | — | |
| SCHEMBL293877 | 0.74 | PARP1 (0.52) | PARP1DAOHTR2ASLC6A2SLC6A4 | |
| SCHEMBL13635655 | 0.74 | PARP1 (0.52) | PARP1DRD2DRD3HTR2ASLC6A2 | |
| SCHEMBL5542419 | 0.74 | PARP1 (0.56) | PARP1DAOHTR2ASLC6A2SLC6A4 | |
| SCHEMBL2007697 | 0.74 | PARP1 (0.52) | PARP1TDP1L3MBTL1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113975408-A | Nano vaccine based on non-methylated CpG, preparation method and application | 上海市肿瘤研究所 | 2022-01-28 | — | — | CN | claimed |
| US-5616232-A | IMMERSING STEEL PLATE IN ACIDIC BATH CONTAINING ZINC AND CHROMIUM IONS AND A POLYOXYETHYLENE-SUBSTITUTED PHENOL DERIVATIVE, ELECTROPLATING | NIPPON STEEL CORPORATION (JP) | 1997-04-01 | — | — | US | claimed |
| EP-0025843-B1 | PREPARATION OF MONOALKYL ETHERS OF HYDROXYPHENOLS AND THEIR TRANSFORMATION INTO HYDROXYCUMARANES | BAYER AG (DE) | 1985-06-19 | — | — | EP | claimed |
| US-4321204-A | Preparation of certain 2-methyl-2,3-dihydro-benzofuran-7-ols | BAYER AKTIENGESELLSCHAFT (DE) | 1982-03-23 | — | — | US | claimed |
| EP-0001486-A2 | Process for preparing 2,3-dihydro-2,2-dimethyl-7-benzofuranol and benzodioxole intermediate therefor | FMC Corporation (US) | 1979-04-18 | — | — | EP | claimed |
| US-20260124156-A1 | PLANT-DERIVED EXTRACELLULAR VESICLE (EVS) COMPOSITIONS AND USES THEREOF | EV BIOSOLUTIONS S P A (IT) | 2026-05-07 | — | — | US | disclosed |
| EP-4705532-A1 | POROUS METAL STRUCTURES INCORPORATING NANOPARTICLES | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-11 | — | — | EP | disclosed |
| EP-4234561-B1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | UNIV NEBRASKA (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250367134-A1 | PERIPHERALIZATION OF CENTRALLY-ACTING CANNABINOID-1 RECEPTOR ANTAGONISTS BY NANOPARTICLES FOR THE TREATMENT METABOLIC RELATED CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-12-04 | — | — | US | disclosed |
| EP-4210669-B1 | PHARMACEUTICAL COMPOSITION IN THE FORM OF A HYDROGEL COMPRISING ORANGE-DERIVED EXTRACELLULAR VESICLES | EVOBIOTECH S R L IN LIQUIDAZIONE (IT) | 2025-08-20 | — | — | EP | disclosed |
| EP-4558623-A1 | ENVELOPED VIRUS LIKE PARTICLES COMPRISING SARS-COV-2 S PROTEIN | National Research Council of Canada (CA) | 2025-05-28 | — | — | EP | disclosed |
| US-20250129033-A1 | METAP2 INHIBITORS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-04-24 | — | — | US | disclosed |
| EP-0001486-A2 | Process for preparing 2,3-dihydro-2,2-dimethyl-7-benzofuranol and benzodioxole intermediate therefor | FMC Corporation (US) | 1979-04-18 | — | — | EP | disclosed |
| EP-0001486-A2 | Process for preparing 2,3-dihydro-2,2-dimethyl-7-benzofuranol and benzodioxole intermediate therefor | FMC Corporation (US) | 1979-04-18 | — | — | EP | disclosed |
| US-4118400-A | THERMAL REARRANGEMENT OF 2-ISOPROPYL-1.3-BENZODIOXOLE, ACID CATALYST | FMC CORPORATION (US) | 1978-10-03 | — | — | US | disclosed |
| US-4118400-A | THERMAL REARRANGEMENT OF 2-ISOPROPYL-1.3-BENZODIOXOLE, ACID CATALYST | FMC CORPORATION (US) | 1978-10-03 | — | — | US | disclosed |
| US-4118400-A | THERMAL REARRANGEMENT OF 2-ISOPROPYL-1.3-BENZODIOXOLE, ACID CATALYST | FMC CORPORATION (US) | 1978-10-03 | — | — | US | disclosed |
| US-4024277-A | INSECTICIDE AND PESTICIDE | FMC CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-4024277-A | INSECTICIDE AND PESTICIDE | FMC CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-4013774-A | INSECTICIDAL N-THIO-SUBSTITUTED CARBAMATES OF DIHYDROBENZOFURANOLS | CHEVRON RESEARCH COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124156-A1 | PLANT-DERIVED EXTRACELLULAR VESICLE (EVS) COMPOSITIONS AND USES THEREOF | EXOSC10, EXOSC9, PHOSPHO1 | PARP1 892/4885BCL2L1 2320/4885BAD 1902/4885 |
| US-20250367134-A1 | PERIPHERALIZATION OF CENTRALLY-ACTING CANNABINOID-1 RECEPTOR ANTAGONISTS BY NANOPARTICLES FOR THE TREATMENT METABOLIC RELATED CONDITIONS | CNR1, CNR2, GPR119 | PARP1 998/4885BCL2L1 3556/4885BAD 1103/4885 |
| US-20250129033-A1 | METAP2 INHIBITORS AND USES THEREOF | METAP2, METAP1, SPINT2 | PARP1 2900/4885BCL2L1 3156/4885BAD 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.